https://scholars.lib.ntu.edu.tw/handle/123456789/543449
標題: | Aflibercept plus FOLFIRI in Asian patients with pretreated metastatic colorectal cancer: A randomized Phase III study | 作者: | Li J. Xu R. Qin S. Liu T. Pan H. Xu J. Bi F. Lim R. Zhang S. Ba Y. Bai Y. Fan N. Tsuji A. KUN-HUEI YEH Ma B. Wei V. Shi D. Magherini E. Shen L. |
關鍵字: | aflibercept; Asia-Pacific; FOLFIRI; mCRC; oxaliplatin-pretreated | 公開日期: | 2018 | 出版社: | Future Medicine Ltd. | 卷: | 14 | 期: | 20 | 起(迄)頁: | 2031-2044 | 來源出版物: | Future Oncology | 摘要: | Aim: To investigate whether the benefit of combining aflibercept with 5-fluorouracil, folinic acid and irinotecan (FOLFIRI) chemotherapy could be confirmed in patients from the Asia-Pacific region (ClinicalTrials.gov: NCT01661270). Patients & methods: Asian patients with oxaliplatin-pretreated metastatic colorectal cancer were randomized to receive aflibercept or placebo, followed by FOLFIRI. The primary end point was progression-free survival. Results: The intention-to-treat population comprised 332 patients. A clinical supply misallocation resulted in 198/332 (60%) patients receiving at least one cycle of misallocated treatment. Nevertheless, the addition of aflibercept to FOLFIRI was shown to improve progression-free survival (hazard ratio: 0.629; 95% CI: 0.488-0.812). Adverse events were in line with expectations. Conclusion: The beneficial treatment effect associated with the addition of aflibercept to FOLFIRI was confirmed in Asian patients with pretreated metastatic colorectal cancer. ? 2018 Lin Shen. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85052125222&doi=10.2217%2ffon-2017-0669&partnerID=40&md5=baa2a8bbcdc26c64f0d66482c20da5bf https://scholars.lib.ntu.edu.tw/handle/123456789/543449 |
ISSN: | 1479-6694 | DOI: | 10.2217/fon-2017-0669 | SDG/關鍵字: | aflibercept; fluorouracil; folinic acid; irinotecan; oxaliplatin; placebo; aflibercept; antineoplastic agent; camptothecin; fluorouracil; folinic acid; fusion protein; vasculotropin receptor; abdominal pain; adult; aged; alopecia; Article; Asian; body weight loss; cancer chemotherapy; China; constipation; continuous infusion; controlled study; decreased appetite; diarrhea; double blind procedure; drug efficacy; drug safety; epistaxis; fatigue; female; Hong Kong; human; hypertension; hypokalemia; intention to treat analysis; Japan; leukopenia; major clinical study; male; metastatic colorectal cancer; middle aged; multicenter study; multiple cycle treatment; nausea; neutropenia; overall survival; phase 3 clinical trial; priority journal; progression free survival; prospective study; proteinuria; randomized controlled trial; side effect; Singapore; stomatitis; Taiwan; thrombocytopenia; treatment response; vomiting; analogs and derivatives; Asian continental ancestry group; cancer staging; clinical trial; colorectal tumor; Kaplan Meier method; metastasis; pathology; retreatment; treatment outcome; very elderly; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Asian Continental Ancestry Group; Camptothecin; Colorectal Neoplasms; Female; Fluorouracil; Humans; Kaplan-Meier Estimate; Leucovorin; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Staging; Receptors, Vascular Endothelial Growth Factor; Recombinant Fusion Proteins; Retreatment; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。